This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HCV; dengue fever	Phospholipase A ₂ group IVA cytosolic calcium-dependent (PLA ₂ G4A; cPLA2-α)	<i>In vitro</i> studies suggest inhibiting PLA ₂ G4A could help treat HCV infection and dengue fever. In human hepatoma cell-based assays of HCV and dengue viral infectivity, a PLA ₂ G4A inhibitor decreased the production of infectious particles and the intracellular infectivity of each virus compared with no treatment. Planned work includes testing PLA ₂ G4A inhibition in animal models of HCV and/or dengue virus infection.	Patented by Twincore GmbH; available for licensing	Menzel, N. <i>et al. PLoS Pathog.</i> ; published online July 26, 2012; doi:10.1371/journal.ppat.1002829 Contact: Thomas Pietschmann, Twincore GmbH, Hannover, Germany e-mail: thomas.pietschmann@twincore.de
<i>SciBX</i> 5(31); doi:10.1038/scibx.2012.816 Published online Aug. 9, 2012				